Stockreport

Novavax: The Bear Case Is Broken, But The Bull Case Needs More Proof [Seeking Alpha]

Sanofi - American Depositary Shares  (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
PDF NVAX's FY26 revenue guidance of $230M–$270M reflects cleaner, high-margin cash flow, excluding potential $200M in milestones from Sanofi. With $857M in cash and recei [Read more]